To read the full publication, visit PubMed.
Theranib Inc. is pleased to highlight a recent review article published in Cancers, titled “The Expanding Role of Cancer Stem Cell Marker ALDH1A3 in Cancer and Beyond” (PMID: 36672441).
This comprehensive review explores the critical role of ALDH1A3 as a cancer stem cell marker and its involvement in tumor growth, metastasis, and therapy resistance. It also examines the mechanisms driving ALDH1A3 overexpression, including genetic amplification and epigenetic modifications, and evaluates the potential of targeting ALDH1A3 for therapeutic intervention.
The findings reinforce the importance of ALDH1A3 as a key target in cancer treatment and underscore the innovative approach Theranib is pursuing with its proprietary inhibitor, CLM296, to address these challenges.